Differences

This shows you the differences between two versions of the page.

--- jesse_papenburg [2022/04/20 00:47]
liam [COVID-19]
+++ jesse_papenburg [2022/11/12 00:00] (current)
liam [Funding]
@@ Line 17: / Line 17: @@
 ==== McGill University ====
-Papenburg is an Assistant Professor of Paediatrics and an Associate Member of the Department of Epidemiology, Biostatistics and Occupational Health at [[McGill University]]. He practices Pediatric Infectious Diseases and Medical Microbiology at the [[Montreal Children's Hospital]] of the [[McGill University Health Centre]].
+Papenburg is an Assistant Professor of Paediatrics and an Associate Member of the Department of Epidemiology, Biostatistics and Occupational Health at [[McGill University]].((//Jesse Papenburg.// (2021, March 4). McGill Newsroom. https://www.mcgill.ca/newsroom/jesse-papenburg)) He practices Pediatric Infectious Diseases and Medical Microbiology at the [[Montreal Children's Hospital]] of the [[McGill University Health Centre]].((//Jesse Papenburg, MD, FRCPC, Pediatric Infectious Disease Specialist and Medical Microbiologist.// Montreal Children’s Hospital. Retrieved April 19, 2022, from https://www.thechildren.com/departments-and-staff/staff/jesse-papenburg-md-frcpc-pediatric-infectious-disease-specialist-and))
+He is also a clinical investigator for the [[MUHC Vaccine Study Centre]].((//About Us.// (2020, July 23). MUHC Vaccine Study Centre; Wayback Machine. https://archive.ph/R2Pr5))
 ==== COVID-19 Immunity Task Force ====
-Papenburg is a scientific advisory on the secretariat of the [[COVID-19 Immunity Task Force]].((Labonne, S. //Secretariat.// COVID-19 Immunity Task Force. Retrieved April 19, 2022, from https://web.archive.org/web/20220322055327/https://www.covid19immunitytaskforce.ca/secretariat/)) The CITF collaborates with the [[Coalition for Epidemic Preparedness Innovations]] (CEPI) on vaccine development.((//Final Version Scientific Strategy, Governance, and Operational Plan.// (2020). COVID-19 Immunity Task Force. https://web.archive.org/web/20220120225658/https://www.covid19immunitytaskforce.ca/wp-content/uploads/2020/11/CITF-Strategic-Plan_Final_ENG_FINAL_2.pdf#page=17))
+Papenburg is a scientific advisor on the secretariat of the [[COVID-19 Immunity Task Force]].((Labonne, S. //Secretariat.// COVID-19 Immunity Task Force. Retrieved April 19, 2022, from https://web.archive.org/web/20220322055327/https://www.covid19immunitytaskforce.ca/secretariat/)) The CITF collaborates with the [[Coalition for Epidemic Preparedness Innovations]] (CEPI) on vaccine development.((//Final Version Scientific Strategy, Governance, and Operational Plan.// (2020). COVID-19 Immunity Task Force. https://web.archive.org/web/20220120225658/https://www.covid19immunitytaskforce.ca/wp-content/uploads/2020/11/CITF-Strategic-Plan_Final_ENG_FINAL_2.pdf#page=17))
 ===== Research =====
@@ Line 41: / Line 42: @@
 ==== Funding ====
-Papenburg is funded by a career award from [[Fonds de Recherche du Québec]], and funding from the [[Quebec Ministry of Health and Social Services]].((Gilca, R., Billard, M.-N., Zafack, J., Papenburg, J., Boucher, F. D., Charest, H., Rochette, M., & De Serres, G. (2020). //Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada.// Preventive Medicine Reports, 20, 101180. https://doi.org/10.1016/j.pmedr.2020.101180)) He has received research funding from the [[CHUM Foundation]] and the [[Canadian Institutes of Health Research]] (CIHR). He has received grants from [[pharmaceutical_companies:MedImmune]] and [[pharmaceutical_companies:Sanofi]], as well as grants and personal fees from [[pharmaceutical_companies:AbbVie]], [[medical_technology_companies:Beckton Dickenson and Company|BD Diagnostics]], [[pharmaceutical_companies:Janssen]], and [[pharmaceutical_companies:Seegene]].((Papenburg, J., Mubareka, S., Allen, U. D., Skowronski, D., Stiver, H. G., Aoki, F. Y., & Evans, G. A. (2020). //Guidance on the use of antiviral agents for the 2019–2020 influenza season.// Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, 5(2), 57–60. https://doi.org/10.3138/jammi.2020-01-13)) ((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay.// Open Forum Infectious Diseases, 8(6). https://doi.org/10.1093/ofid/ofab220)) ((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay.// medRxiv. Preprint. https://doi.org/10.1101/2021.01.23.21250325)) He has also received consulting fees from [[pharmaceutical_companies:Merck]], and personal fees from [[pharmaceutical_companies:Cepheid]] and [[pharmaceutical_companies:Roche]].((Cheng, M. P., Papenburg, J., Desjardins, M., Kanjilal, S., Quach, C., Libman, M., Dittrich, S., & Yansouni, C. P. (2020). //Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2.// Annals of Internal Medicine, 172(11), 726–734. https://doi.org/10.7326/m20-1301)) ((Merckx, J., Cooke, S., El Tal, T., Bitnun, A., Morris, S. K., Yeh, E. A., Yea, C., Gill, P., Papenburg, J., Lefebvre, M.-A., Scuccimarri, R., Ulloa-Gutierrez, R., Brenes-Chacon, H., Yock-Corrales, A., Ivankovich-Escoto, G., Soriano-Fallas, A., Mezerville, M. H., Dewan, T., Restivo, L., & Nateghian, A. (2022). //Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study.// Canadian Medical Association Journal, 194(14), E513–E523. https://doi.org/10.1503/cmaj.210873)) He has also published research funded by the [[Janeway Children's Hospital Foundation]]. He also served on a Scientific Steering Committee for AbbVie.((Papenburg, J., & Harrison, R. (2021, October 27). //Seasonal Influenza Immunization 2021-2022.// National Collaborating Centre for Infectious Diseases. https://web.archive.org/web/20220419211302/https://nccid.ca/wp-content/uploads/sites/2/2021/12/DATAPOST-Rev-EN-Seasonal-Influenza-Webinar-2021-2022_Nov-23.LFpptm.pdf))
+Papenburg is funded by a career award from [[Fonds de Recherche du Québec]], and funding from the [[Quebec Ministry of Health and Social Services]].((Gilca, R., Billard, M.-N., Zafack, J., Papenburg, J., Boucher, F. D., Charest, H., Rochette, M., & De Serres, G. (2020). //Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada.// Preventive Medicine Reports, 20, 101180. https://doi.org/10.1016/j.pmedr.2020.101180)) He has received research funding from the [[CHUM Foundation]] and the [[Canadian Institutes of Health Research]] (CIHR).((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay.// Open Forum Infectious Diseases, 8(6). https://doi.org/10.1093/ofid/ofab220)) He has received grants from [[pharmaceutical_companies:MedImmune]] and [[pharmaceutical_companies:Sanofi]], as well as grants and personal fees from [[pharmaceutical_companies:AbbVie]], [[medical_technology_companies:Beckton Dickenson and Company|BD Diagnostics]], [[pharmaceutical_companies:Janssen]], and [[pharmaceutical_companies:Seegene]].((Papenburg, J., Mubareka, S., Allen, U. D., Skowronski, D., Stiver, H. G., Aoki, F. Y., & Evans, G. A. (2020). //Guidance on the use of antiviral agents for the 2019–2020 influenza season.// Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, 5(2), 57–60. https://doi.org/10.3138/jammi.2020-01-13)) ((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay.// Open Forum Infectious Diseases, 8(6). https://doi.org/10.1093/ofid/ofab220)) ((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay.// medRxiv. Preprint. https://doi.org/10.1101/2021.01.23.21250325)) He has also received consulting fees from [[pharmaceutical_companies:Merck]], and personal fees from [[pharmaceutical_companies:Cepheid]] and [[pharmaceutical_companies:Roche]].((Cheng, M. P., Papenburg, J., Desjardins, M., Kanjilal, S., Quach, C., Libman, M., Dittrich, S., & Yansouni, C. P. (2020). //Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2.// Annals of Internal Medicine, 172(11), 726–734. https://doi.org/10.7326/m20-1301)) ((Merckx, J., Cooke, S., El Tal, T., Bitnun, A., Morris, S. K., Yeh, E. A., Yea, C., Gill, P., Papenburg, J., Lefebvre, M.-A., Scuccimarri, R., Ulloa-Gutierrez, R., Brenes-Chacon, H., Yock-Corrales, A., Ivankovich-Escoto, G., Soriano-Fallas, A., Mezerville, M. H., Dewan, T., Restivo, L., & Nateghian, A. (2022). //Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study.// Canadian Medical Association Journal, 194(14), E513–E523. https://doi.org/10.1503/cmaj.210873)) He has also published research funded by the [[Janeway Children's Hospital Foundation]]. He also served on a Scientific Steering Committee for AbbVie.((Papenburg, J., & Harrison, R. (2021, October 27). //Seasonal Influenza Immunization 2021-2022.// National Collaborating Centre for Infectious Diseases. https://web.archive.org/web/20220419211302/https://nccid.ca/wp-content/uploads/sites/2/2021/12/DATAPOST-Rev-EN-Seasonal-Influenza-Webinar-2021-2022_Nov-23.LFpptm.pdf))
+Papenburg appeared in a feature article discussing his many media appearances related to [[COVID-19]], and solicited donations for more COVID-19 research to the [[Montreal Children's Hospital Foundation]].((//The Children’s COVID-19 media authority: Dr. Jesse Papenburg.// Montreal Children’s Hospital Foundation. Retrieved April 19, 2022, from https://web.archive.org/web/20220419225627/https://fondationduchildren.com/en/heroes/the-childrens-covid-19-media-authority-dr-jesse-papenburg))